These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 30316174)

  • 1. Bacterial and CMV pneumonia in a patient treated with alemtuzumab for multiple sclerosis.
    Buonomo AR; Saccà F; Zappulo E; De Zottis F; Lanzillo R; Gentile I; Carotenuto A; Borgia G; Russo CV
    Mult Scler Relat Disord; 2019 Jan; 27():44-45. PubMed ID: 30316174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab.
    Clerico M; De Mercanti S; Artusi CA; Durelli L; Naismith RT
    Mult Scler; 2017 May; 23(6):874-876. PubMed ID: 28290755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic microabscesses during CMV reactivation in a multiple sclerosis patient after alemtuzumab treatment.
    Barone S; Scannapieco S; Torti C; Filippelli E; Pisani V; Granata A; Console D; Demonte G; Tallarico T; Polidoro S; Quattrone A; Valentino P
    Mult Scler Relat Disord; 2018 Feb; 20():6-8. PubMed ID: 29272733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Listeria Meningitis Complicating Alemtuzumab Treatment in Multiple Sclerosis--Report of Two Cases.
    Rau D; Lang M; Harth A; Naumann M; Weber F; Tumani H; Bayas A
    Int J Mol Sci; 2015 Jun; 16(7):14669-76. PubMed ID: 26132570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytomegalovirus primary infection in a patient with multiple sclerosis treated with alemtuzumab.
    Aguirre C; Meca-Lallana V; Sánchez P; Vivancos J
    Mult Scler Relat Disord; 2019 Oct; 35():270-271. PubMed ID: 31442904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thyroid disorders in alemtuzumab-treated multiple sclerosis patients: a Belgian consensus on diagnosis and management.
    Decallonne B; Bartholomé E; Delvaux V; D'haeseleer M; El Sankari S; Seeldrayers P; Van Wijmeersch B; Daumerie C
    Acta Neurol Belg; 2018 Jun; 118(2):153-159. PubMed ID: 29372482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytomegalovirus Immunity After Alemtuzumab Induction in Desensitized Kidney Transplant Patients.
    Ge S; Karasyov A; Sinha A; Petrosyan A; Lovato D; Thomas DL; Vo A; Jordan SC; Toyoda M
    Transplantation; 2017 Jul; 101(7):1720-1726. PubMed ID: 27841845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic erythematous lupus after treatment of multiple sclerosis with alemtuzumab.
    Adamec I; Mayer M; Ćorić M; Ruška B; Habek M
    Mult Scler Relat Disord; 2020 Nov; 46():102589. PubMed ID: 33296985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of immune thrombocytopenia in multiple sclerosis patients treated with alemtuzumab: a Belgian consensus.
    Lambert C; Dubois B; Dive D; Lysandropoulos A; Selleslag D; Vanopdenbosch L; Van Pesch V; Vanwijmeersch B; Janssens A
    Acta Neurol Belg; 2018 Mar; 118(1):7-11. PubMed ID: 29380254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alemtuzumab (LEMTRADA) and multiple sclerosis. Biased evaluation, evidence of serious risks.
    Prescrire Int; 2015 Mar; 24(158):69. PubMed ID: 25897458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute respiratory distress syndrome following alemtuzumab therapy for relapsing multiple sclerosis.
    Yann K; Jackson F; Sharaf N; Mihalova T; Talbot P; Rog D; Pace A
    Mult Scler Relat Disord; 2017 May; 14():1-3. PubMed ID: 28619423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alemtuzumab treatment of multiple sclerosis.
    Coles AJ
    Semin Neurol; 2013 Feb; 33(1):66-73. PubMed ID: 23709214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond.
    Ruck T; Bittner S; Wiendl H; Meuth SG
    Int J Mol Sci; 2015 Jul; 16(7):16414-39. PubMed ID: 26204829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The outlook for alemtuzumab in multiple sclerosis.
    Williams T; Coles A; Azzopardi L
    BioDrugs; 2013 Jun; 27(3):181-9. PubMed ID: 23558379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.
    Cohen JA; Coles AJ; Arnold DL; Confavreux C; Fox EJ; Hartung HP; Havrdova E; Selmaj KW; Weiner HL; Fisher E; Brinar VV; Giovannoni G; Stojanovic M; Ertik BI; Lake SL; Margolin DH; Panzara MA; Compston DA;
    Lancet; 2012 Nov; 380(9856):1819-28. PubMed ID: 23122652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Alemtuzumab, a monoclonal antibody against CD52: hopes and fears].
    Mori M
    Brain Nerve; 2014 Oct; 66(10):1179-89. PubMed ID: 25296872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of an anti-infective screening and monitoring protocol together with infectious disease consultation in preventing infective adverse events in patients treated with anti-CD20/CD52 agents for multiple sclerosis.
    Zappulo E; Buonomo AR; Moccia M; Pinchera B; Villari R; Petracca M; Lanzillo R; Scotto R; Carotenuto A; Viceconte G; Schiano Moriello N; Bruno L; Gentile I; Brescia Morra V
    Mult Scler Relat Disord; 2022 Jul; 63():103814. PubMed ID: 35487032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytomegalovirus Pneumonia after Anti-CC-chemokine Receptor 4 Monoclonal Antibody (Mogamulizumab) Therapy in an Angioimmunoblastic T-cell Lymphoma Patient.
    Ishii Y; Itabashi M; Numata A; Yamamoto W; Motohashi K; Hagihara M; Matsumoto K; Fujisawa S
    Intern Med; 2016; 55(6):673-5. PubMed ID: 26984089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alemtuzumab for Multiple Sclerosis.
    Willis MD; Robertson NP
    Curr Neurol Neurosci Rep; 2016 Sep; 16(9):84. PubMed ID: 27485945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alemtuzumab in the treatment of multiple sclerosis: patient selection and special considerations.
    Dörr J; Baum K
    Drug Des Devel Ther; 2016; 10():3379-3386. PubMed ID: 27799738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.